van Heek, Lutz, Stuka, Colin, Kaul, Helen, Mueller, Horst, Mettler, Jasmin, Hitz, Felicitas, Baues, Christian, Fuchs, Michael, Borchmann, Peter, Engert, Andreas, Dietlein, Markus, Voltin, Conrad-Amadeus and Kobe, Carsten (2022). Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. BMC Cancer, 22 (1). LONDON: BMC. ISSN 1471-2407

Full text not available from this repository.

Abstract

Background: F-18 -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD16 trial. Methods: F-18-FDG PET/CT images were available for MTV and TLG analysis in 107 cases from the HD16 trial. We calculated MTV and TLG using three different threshold methods (SUV4.0,SUV(41% )and SUV140%L), and then performed receiver-operating-characteristic analysis to assess the predictive impact of these parameters in predicting an adequate therapy response with PET negativity after 2 cycles of chemotherapy. Results: All three threshold methods analyzed for MTV and TLG calculation showed a positive correlation with the PET response after 2 cycles chemotherapy. The largest area under the curve (AUC) was observed using the fixed threshold of SUV4.0 for MTV- calculation (AUC 0.69 [95% CI 0.55-0.83]) and for TLG-calculation (AUC 0.69 [0.55-0.82]). The calculations for MTV and TLG with a relative threshold showed a lower AUC: using SUV140%L AUCs of 0.66 [0.53-0.80] for MTV and 0.67 for TLG [0.54-0.81]) were observed, while with SUV41% an AUC of 0.61 [0.45-0.76] for MTV, and an AUC 0.64 [0.49-0.80]) for TLG were seen. Conclusions: MTV and TLG do have a predictive value after two cycles ABVD in early stage Hodgkin lymphoma, particularly when using the fixed threshold of SUV4.0 for MTV and TLG calculation.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
van Heek, LutzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stuka, ColinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kaul, HelenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller, HorstUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mettler, JasminUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hitz, FelicitasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baues, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuchs, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borchmann, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Engert, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dietlein, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Voltin, Conrad-AmadeusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kobe, CarstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-671160
DOI: 10.1186/s12885-022-09758-z
Journal or Publication Title: BMC Cancer
Volume: 22
Number: 1
Date: 2022
Publisher: BMC
Place of Publication: LONDON
ISSN: 1471-2407
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
POSITRON-EMISSION-TOMOGRAPHY; OPEN-LABEL; EARLY RELAPSE; CHEMOTHERAPY; RADIOTHERAPY; INTERIM; INTENSITY; THERAPYMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/67116

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item